← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
Cell-Type-Specific TFEB Modulation Combined with Trehalose f (TFEB) — 0.00 Alpha-theta entrainment therapy to enhance default mode netw (SST) — 0.00 GLUT1-Mediated Carrier-Conjugate Delivery Strategy (LDLR) — 0.00 TBK1 Loss Triggers eIF2α-Mediated Translational Repression T (TBK1, EIF2S1) — 0.00 LDLR-Primed LRP1 Transcytosis with pH-Responsive Escape Stra (LDLR) — 0.00 LAMP2A Upregulation to Enhance Chaperone-Mediated Autophagy (LAMP2A) — 0.00 Closed-loop transcranial focused ultrasound with gamma entra (PVALB) — 0.00 TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio (TBK1 → NF-κB / IRF3 / p62-autophagy / SASP effectors) — 0.00 Closed-loop transcranial focused ultrasound to restore hippo (SST) — 0.00 LAMP1 Overexpression to Enhance Lysosomal Capacity Independe (LAMP1) — 0.00 eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote (EIF2S1,eIF2α,PERK,GCN2,ATF4,TOMM20,TIMM23,NDUFS1,NDUFS3,COX4I1,COX5A,mitochondrial protein import) — 0.00 LDLR-Mediated Neurosteroid Precursor Delivery Strategy (LDLR) — 0.00 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.97 GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl (GRIN2B) — 0.96 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.96 Cortico-Striatal Synchrony Restoration via NMDA Modulation (GRIN2B) — 0.95 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.95 Plasma NfL Elevation Secondary to BBB-Associated Transport D (NEFL) — 0.94 Microglial-Mediated Tau Clearance Dysfunction via TREM2 Rece (MAPT) — 0.94 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.92 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 eIF2α Phosphorylation Imbalance Creates Integrated Stress Re (EIF2S1,eIF2α,PERK,GCN2,ATF4,ATF5,CHOP,DDIT3,integrated stress response,protein synthesis) — 0.90 APOE-Dependent Autophagy Restoration (MTOR) — 0.89 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 p38α Inhibitor and PRMT1 Activator Combination to Restore Ph (MAPK14/PRMT1) — 0.89 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.89 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.89 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.89
Add
|
× A lower-dose 50-100 mg/da
IL6; TGFB1; AIF1; MAPK14; MAPK8; NFKB1 · neurodegeneration · -
Composite 0.480
Price $0.50
Evidence For 0
Evidence Against 0
Trazodone may have a secondary low-dose mechanism through astrocyte and microglial inflammatory modulation, potentially shifting GFAP, IL-6, YKL-40, or kynurenine-pathway markers. This is the weakest surviving biological mechanism worth embedding in a trial as a secondary pharmacodynamic package, not as a lead disease-modifying hypothesis.
Radar Chart — 10 Dimensions
Score Breakdown
Dimension A lower-dose 50-100 mg/day gli Mechanistic 0.440 Evidence 0.340 Novelty 0.540 Feasibility 0.660 Impact 0.410 Druggability 0.590 Safety 0.620 Competition 0.430 Data 0.410 Reproducible 0.330 KG Connect 0.500
Evidence A lower-dose 50-100 mg/day glial anti-inflammatory effect ma No evidence citations yet
Price History Overlay